drugset / Trial / NCT00873223

Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir

NCT00873223

Phase 1 Completed 33 enrolled Novo Nordisk A/S
Non-randomizedCrossoverOpen-labelTreatment

Summary

This trial is conducted in the United States. The aim of this clinical trial is to investigate whether chronic liraglutide administration affects the mode of action (pharmacokinetics) of insulin detemir

Timeline

Start
2009-03
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Subcutaneous
Subject insulin detemir Protein / enzyme biologic 0.5 iu/kg